The study, led by Dr. Hollis O'Neal, M.D., LSU Healthcare Network Pulmonary-Critical Care, Our Lady of the Lake Regional Medical Center, Baton Rouge, LA, will commence immediately. Initial data is expected to be available within 60 days, depending on enrollment.
Sepsis is a serious public health threat, killing approximately 270,000 Americans each year.
The condition is the result of an extreme response to infection that can lead quickly to organ failure and death. Minutes can become a matter of life and death in the accurate diagnosis, triage and treatment of critically ill patients with suspected sepsis.
By looking at the structure of immune cells through high-speed imaging, machine learning and microfluidics, Cytovale's patented technology can diagnose sepsis in under 10 minutes with the goal of enabling timely and accurate triage in the emergency department, filling a crucial unmet need in rapid sepsis diagnosis.
BARDA is continuing to fund advanced research and development activities to support the FDA 510(k) clearance for the Cytovale Rapid Sepsis Diagnostic System.
BARDA and Cytovale are demonstrating a continued commitment to their public-private partnership, first announced in October 2019, with BARDA now contributing an additional USD 3.83m of the USD 5.9m total estimated cost to continue validation and advanced research, including the pilot study of COVID-19 patients.
Cytovale will fund the remaining research and development costs for this study.
Cytovale, based in San Francisco, Calif., is a medical technology company dedicated to revolutionizing diagnostics using cell mechanics and machine learning, and applying this first to sepsis, a condition whose early detection dramatically improves patient outcomes.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients